Home Duke University Press
QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Neuro Oncol 1999 1(1):69-80; DOI:10.1215/15228517-1-1-69
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levin, V. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Duke University Press

Symposium Genetic Classification and Treatment of Malignant Gliomas and Oligodendrogliomas

Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: The past decade and where we are heading

Victor A. Levin2

Department of Neuro-Oncology and the Brain Tumor Center, M.D. Anderson Cancer Center, University of Texas, Houston, TX 77030

2 Address correspondence and reprint requests to Victor A. Levin, MD, Department of Neuro-Oncology-100, M.D. Anderson Cancer Center, University of Texas, 1515 Holcombe Boulevard, Houston, TX 77030.

Abstract

Over the past three decades, we have made great strides in the treatment of most, but not all, brain tumors. Dramatic advances have occurred in diagnostic imaging, neurosurgery, neuroanesthesia, radiotherapy, and chemotherapy for CNS tumors. Unfortunately, our progress has not yet met our expectations. Because of the infiltrative nature of most primary brain tumors, neurosurgery can never be expected to be curative for the majority of gliomas. Because infiltrative tumors interdigitate with normal brain cells and are not highly sensitive to irradiation, one cannot expect radiotherapy to be curative without serious damage to normal brain cells. The hope for a cure, then, rests with chemotherapy. Those who administer chemotherapy to patients with CNS tumors fully expect that, in time, long-term survival and, ultimately, the cure will become an everyday reality. To achieve that reality, however, new treatment concepts and drugs are needed.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. A. Brandes, E. Franceschi, A. Tosoni, M. E. Hegi, and R. Stupp
Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments
Clin. Cancer Res., February 15, 2008; 14(4): 957 - 960.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
S. L. Chua, M. A. Rosenthal, S. S. Wong, D. M. Ashley, A.-m. Woods, A. Dowling, and L. M. Cher
Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme
Neuro-oncol, January 1, 2004; 6(1): 38 - 43.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Bello, C. Giussani, G. Carrabba, M. Pluderi, V. Lucini, M. Pannacci, D. Caronzolo, G. Tomei, R. Villani, F. Scaglione, et al.
Suppression of Malignant Glioma Recurrence in a Newly Developed Animal Model by Endogenous Inhibitors
Clin. Cancer Res., November 1, 2002; 8(11): 3539 - 3548.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Rosenthal, B. Kavar, J. S. Hill, D. J. Morgan, R. L. Nation, S. S. Stylli, R. L. Basser, S. Uren, H. Geldard, M. D. Green, et al.
Phase I and Pharmacokinetic Study of Photodynamic Therapy for High-Grade Gliomas Using a Novel Boronated Porphyrin
J. Clin. Oncol., January 15, 2001; 19(2): 519 - 524.
[Abstract] [Full Text] [PDF]


  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


Copyright 1999 by Society for Neuro-Oncology